Evidence map›Paper›PMID 36933035›Full record

ArticleJournal of cancer research and clinical oncology2023

Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer.

Huan Qin, Haiyan Hu, Ximing Liao, Pei Zhao, Wenjuan He, Xiaoping Su, Jiaxing Sun, Qiang Li

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Huan Qin *Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Haiyan HuBreast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, 266071, China.
Ximing LiaoDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Pei ZhaoDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Wenjuan HeDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Xiaoping SuSchool of Basic Medicine, Wenzhou Medical University, Wenzhou Tea Mountain Higher Education Park, Wenzhou, 325000, China.
Jiaxing Sun *Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China. jiaxing20022001@163.com.
Qiang LiDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. liqressh1962@163.com.
Shanghai East Hospital · CNAffiliated Hospital of Qingdao University · CNQingdao University · CNWenzhou Medical University · CN

Funding

Health & Medicine and Scientific Technology Development Program of Shandong Province 202203020560Shanghai Science and Technology Committee Scientific Research Project 19411950400Youth Scientific Research Foundation of Affiliated Hospital of Qingdao University QDFYQN202101014
6 · The paper itself

Abstract

purposeNeoantigens produced from mutations in tumors are important targets of T-cell-based immunotherapy and immune checkpoint blockade has been approved for treating multiple solid tumors. We investigated the potential benefit of adoptive neoantigen-reactive T (NRT) cells in combination with programmed cell death protein 1 inhibitor (anti-PD1) for treating lung cancer in a mouse model.

methodsNRT cells were prepared by co-culturing T cells and neoantigen-RNA vaccine-induced dendritic cells. Then, adoptive NRT cells in combination with anti-PD1 were administered to tumor-bearing mice. Pre- and post-therapy cytokine secretion, antitumor efficacy, and tumor microenvironment (TME) changes were determined both in vitro and in vivo.

resultsWe successfully generated NRT cells based on the 5 neoantigen epitopes identified in this study. NRT cells exhibited an enhanced cytotoxic phenotype in vitro and the combination therapy led to attenuated tumor growth. In addition, this combination strategy downregulated the expression of the inhibitory marker PD-1 on tumor-infiltrating T cells and promoted the trafficking of tumor-specific T cells to the tumor sites.

conclusionThe adoptive transfer of NRT cells in association with anti-PD1 therapy can exert an antitumor effect on lung cancer, and is a feasible, effective, and novel immunotherapy regimen for treating solid tumors.

Indexed as

Lung NeoplasmsT-LymphocytesAnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesImmune Checkpoint InhibitorsImmunotherapyMiceTumor MicroenvironmentAntigens, NeoplasmImmune Checkpoint InhibitorsAdoptive cell therapyLung cancerNeoantigen-reactive T cellProgrammed cell death protein 1 inhibitorVaccine

Identifiers

PMID36933035
PMCPMC10024025
OpenAlexW4327752202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.